Abstract 2082P
Background
Medical cannabis (MC) has garnered significant attention as a potential strategy for cancer care. Attitudes and beliefs of medical professionals regarding its efficacy and safety remain diverse and inconclusive. This survey explores medical professionals' knowledge, attitudes, and barriers towards MC for cancer care. It aims to understand their beliefs on efficacy and safety, benefits and risks, and identify barriers to its use.
Methods
175 medical professionals worldwide completed a 31-item survey that included demographics, knowledge and attitudes towards MC, perceived benefits and risks, and willingness to recommend MC to patients. Data analysis involved descriptive statistics and Chi-square tests.
Results
The survey included respondents with a balanced male-to-female ratio and a median age of 37 years from 31 countries, with 120 from upper-middle-income countries (UMIC) and 55 from lower-middle-income countries (LMIC). Findings revealed that 44% of respondents were familiar with MC, and 51% claimed to have received information about it from patients, with 35% receiving direct prescription requests. Surprisingly, only 16% had prescribed MC for symptoms such as CINV, pain, anorexia, cachexia, psychiatric symptoms, insomnia, muscle spasms. There were no significant associations between knowledge levels or patient prescription requirements and income level, but a significant association was found between drug prescription and UMICs. (p = 0.003). Notably, only 9% of participants were knowledgeable about their country's MC legislation, although most believed that legislative and social stigma posed significant barriers to its use.
Conclusions
The survey revealed significant variations in the knowledge and attitudes of medical oncologists towards MC in cancer care. Geographic differences were also observed, with professionals from UMICs more inclined to prescribe MC. These findings underscore the need for enhanced education and training for medical professionals regarding the use of MC in cancer care, thereby informing future research and clinical practices in this field.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2076P - Topical diclofenac for prevention of HFS in patients receiving capecitabine monotherapy: An exploratory subgroup analysis of the D-ToRCH phase III trial
Presenter: Akhil Santhosh
Session: Poster session 06
2077P - A randomized, placebo-controlled trial assessing the efficacy and safety of the combination of superoxide dismutase, alpha lipoic acid, vitamin B12, B1, B2, B6, E, Mg, Zn and a fatty acid for 6 months in the management of chemotherapy induced neuropathic pain
Presenter: Triantafylos Didangelos
Session: Poster session 06
2078P - Evaluation of chemotherapy-induced nausea and vomiting beyond the delayed phase: Results of a survey of healthcare providers in Japan
Presenter: Florian Scotté
Session: Poster session 06
2079P - Naloxegol for the treatment of opioid-induced constipation in patients with cancer pain: A pooled analysis of real-world studies (NALOPOOL)
Presenter: Maria del Carmen Beato Zambrano
Session: Poster session 06
2080P - Incidence and risks of intravenous chemotherapy-induced neutropenia (ICIN) in oncology: A multicenter retrospective cohort study on real-life data
Presenter: Olivia Rohr
Session: Poster session 06
2081P - The therapeutic effect of anti-inflammatory tripeptide cream on hand-foot syndrome related to anticancer drugs: A prospective, randomized, placebo-controlled pilot trial
Presenter: Yaewon Yang
Session: Poster session 06
2083P - Association between VTE location and risk of recurrent, bleeding and death in the international prospective TESEO SEOM cancer cohort
Presenter: Rocío Martín Lozano
Session: Poster session 06
2084P - Cardiovascular (CV) mortality among metastatic cancer patients: A retrospective cohort study
Presenter: Irbaz Riaz
Session: Poster session 06
2085P - Buprenorphine use and cancer outcomes
Presenter: Nosayaba Osazuwa-Peters
Session: Poster session 06